A promising drug , retatrutide, is sparking considerable buzz within the Oz weight management community. Created by Eli Lilly , this dual GIP and GLP-1 receptor appears to deliver more impressive outcomes than existing therapies. Early scientific studies have shown noteworthy diminutions in physical weight , suggesting the potential for a new strat